LVW Advisors
VRTX icon

LVW Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

LVW Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$492K Buy
942
+44
+5% +$22.5K 0.04% 259
2026
Q2 		$446K Sell
898
-190
-17% -$84.2K 0.04% 254
2026
Q1 		$486K Sell
1,088
-386
-26% -$180K 0.05% 219
2025
Q4 		$668K Buy
1,474
+503
+52% +$217K 0.07% 143
2025
Q3 		$380K Buy
971
+158
+19% +$66K 0.04% 236
2025
Q2 		$362K Buy
813
+19
+2% +$8.76K 0.04% 240
2025
Q1 		$385K Buy
794
+28
+4% +$13K 0.05% 210
2024
Q4 		$308K Sell
766
-26
-3% -$12.1K 0.04% 246
2024
Q3 		$368K Buy
792
+50
+7% +$24K 0.05% 214
2024
Q2 		$348K Buy
742
+129
+21% +$56K 0.05% 211
2024
Q1 		$256K Buy
+613
New +$259K 0.04% 249

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

LVW Advisors's VRTX Position: Q3 2026 in Review

LVW Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 4.9% in Q3 2026, buying an estimated $22.5K and bringing the position to 942 shares worth $492K. The position accounts for 0.04% of the portfolio, ranked #259.

LVW Advisors first reported a position in VRTX in Q1 2024 and has held it in 11 quarters since. The position peaked at $668K in Q4 2025. 653 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • LVW Advisors held 942 shares of Vertex Pharmaceuticals worth $492K as of Q3 2026.
  • LVW Advisors bought 44 Vertex Pharmaceuticals shares in Q3 2026, an estimated $22.5K.
  • Vertex Pharmaceuticals made up 0.04% of LVW Advisors's portfolio in Q3 2026, its #259 holding.
  • LVW Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • LVW Advisors's Vertex Pharmaceuticals position peaked at $668K in Q4 2025.
  • 653 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on LVW Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.